In the current study, we show that SREBP-1 mediated lipogenic pathway is a key mediator of oncogenic EGFR and that its constitutive activation contributes to gefitinib-acquired resistance in EGFR mutant lung cancer. The gene discussed is EGFR; the disease is lung cancer.